National Cooperative Growth Study in CKD

Completed

• Conditions: Growth Hormone Deficiency

• Registration Number: NCT00616278
• Lead Sponsor: University of California, Davis

Brief Summary

The purpose of this study is to learn whether growth hormone being administered to children with Chronic Kidney Disease is effective and if it has any side effects.

Detailed Description

Not available

Study Timeline

• Study Start: 2005-10
• Study First Submitted: 2008-02-04
• Study First Submitted QC: 2008-02-14
• Study First Posted: 2008-02-15
• Primary Completion: 2010-02
• Study Completion: 2010-02
• Status Verified: 2017-05
• Last Update Submitted: 2017-05-25
• Last Update Posted: 2017-05-30

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 27

Inclusion Criteria

• Must be a patient of the UC Davis Medical Center pediatric clinic with Chronic Kidney Disease

Exclusion Criteria

• Greater than 18 years old
• Not a patient at the UC Davis Medical Center pediatric clinic

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
The primary outcome measures of the NCGS are ongoing safety and efficacy of Genentech GH preparations in pediatric growth disorders for which GH is initiated.	per the study, the pt will be on GH treatement until the physician instructs them to stop

Trial Locations

Locations (1)

UC Davis Medical Center; 🇺🇸 Sacramento, California, United States